Transitional Cell Carcinoma
Welcome,         Profile    Billing    Logout  
 49 Companies   64 Products   64 Products   51 Mechanisms of Action   1 Trial   275 News 


«123456»
  • ||||||||||  mitomycin / Generic mfg.
    Enrollment change, Trial termination, Trial primary completion date:  Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Gu (clinicaltrials.gov) -  Oct 10, 2014   
    P3,  N=190, Terminated, 
    Trial primary completion date: Jan 2015 --> Jan 2016 N=300 --> 190 | Recruiting --> Terminated | Trial primary completion date: Dec 2011 --> Dec 2013; slow accrual
  • ||||||||||  cisplatin / Generic mfg., pemetrexed / Generic mfg.
    Trial completion, Trial primary completion date, Combination therapy, Metastases:  PECULIAR: Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma (clinicaltrials.gov) -  Sep 28, 2014   
    P2,  N=42, Completed, 
    N=40 --> 22 Recruiting --> Completed | Trial primary completion date: Dec 2012 --> Dec 2013
  • ||||||||||  INCB47986 / Incyte
    Enrollment closed, Enrollment change, Trial primary completion date, IO biomarker, Metastases:  An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies (clinicaltrials.gov) -  Aug 15, 2014   
    P1,  N=100, Active, not recruiting, 
    Withdrawn --> Completed | Initiation date: Jan 2005 --> Oct 2001 | Trial primary completion date: Jan 2005 --> Jan 2014 Not yet recruiting --> Active, not recruiting | N=60 --> 100 | Trial primary completion date: Oct 2015 --> Oct 2014
  • ||||||||||  gefitinib / Generic mfg., docetaxel / Generic mfg.
    Trial completion, Enrollment change, Trial primary completion date, Combination therapy, Metastases:  Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer (clinicaltrials.gov) -  Aug 11, 2014   
    P2,  N=50, Completed, 
    Not yet recruiting --> Active, not recruiting | N=60 --> 100 | Trial primary completion date: Oct 2015 --> Oct 2014 Active, not recruiting --> Completed | N=90 --> 50 | Trial primary completion date: Aug 2015 --> Aug 2014
  • ||||||||||  cisplatin / Generic mfg.
    Trial completion, Enrollment change, Trial primary completion date:  Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer. (clinicaltrials.gov) -  Aug 4, 2014   
    P3,  N=67, Completed, 
    Trial primary completion date: Jun 2014 --> Feb 2015 Active, not recruiting --> Completed | N=150 --> 67 | Trial primary completion date: Nov 2009 --> Feb 2010
  • ||||||||||  Caprelsa (vandetanib) / Sanofi
    Trial completion, Metastases:  Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC (clinicaltrials.gov) -  Jun 3, 2014   
    P2,  N=149, Completed, 
    Active, not recruiting --> Completed | N=25 --> 18 Active, not recruiting --> Completed
  • ||||||||||  Votrient (pazopanib) / Novartis
    Trial completion date, Metastases:  Pazopanib in Treating Patients With Metastatic Urothelial Cancer (clinicaltrials.gov) -  May 21, 2014   
    P2,  N=19, Completed, 
    Active, not recruiting --> Completed Trial completion date: Dec 2010 --> Dec 2013
  • ||||||||||  sunitinib / Generic mfg.
    Trial primary completion date, Metastases:  Gemzar, Cisp, Sunitinib Urothelial Ca (clinicaltrials.gov) -  May 19, 2014   
    P2,  N=36, Completed, 
    Trial completion date: Dec 2010 --> Dec 2013 Trial primary completion date: Jun 2012 --> Aug 2012
  • ||||||||||  sunitinib / Generic mfg.
    Trial completion date, Metastases:  Gemzar, Cisp, Sunitinib Urothelial Ca (clinicaltrials.gov) -  May 19, 2014   
    P2,  N=36, Completed, 
    Trial primary completion date: Jun 2012 --> Aug 2012 Trial completion date: Jun 2012 --> Aug 2012
  • ||||||||||  sunitinib / Generic mfg.
    Trial completion, Metastases:  Gemzar, Cisp, Sunitinib Urothelial Ca (clinicaltrials.gov) -  May 19, 2014   
    P2,  N=36, Completed, 
    Trial completion date: Jun 2012 --> Aug 2012 Active, not recruiting --> Completed
  • ||||||||||  cabazitaxel / Generic mfg.
    Trial completion date, Metastases:  A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC) (clinicaltrials.gov) -  May 11, 2014   
    P2,  N=48, Recruiting, 
    Trial primary completion date: May 2014 --> May 2015 Trial completion date: Jul 2015 --> Jul 2016
  • ||||||||||  Ixempra (ixabepilone) - Otsuka, R / Pharm, patupilone (EPO 906) / Novartis
    Trial completion, Metastases:  Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer (clinicaltrials.gov) -  Feb 19, 2014   
    P2,  N=45, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  arsenic trioxide / Generic mfg.
    Trial completion:  Arsenic Trioxide in Treating Patients With Urothelial Cancer (clinicaltrials.gov) -  Feb 19, 2014   
    P2,  N=35, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion:  Eflornithine in Treating Patients With Bladder Cancer (clinicaltrials.gov) -  Feb 19, 2014   
    P3,  N=450, Completed, 
    Active, not recruiting --> Completed No longer recruiting --> Completed
  • ||||||||||  carboplatin / Generic mfg., measles vaccine / Generic mfg., paclitaxel / Generic mfg.
    Trial completion:  Combination Chemotherapy in Treating Patients With Bladder Cancer (clinicaltrials.gov) -  Feb 19, 2014   
    P3,  N=490, Completed, 
    No longer recruiting --> Completed Active, not recruiting --> Completed